Phase 2 N=10 A Study Examining the Medication Apremilast as Treatment for Chronic Itch
Itch
Primary: Absolute NRS Itch Score at Week 16 (End of Treatment) — 7; 7.5 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Itch Relieving Effect of Botox: a Study in Healthy Subjects
Pruritus
Primary: Itch by VAS Itch Intensity at Baseline (Visit 1) — 4.5; 4.3; 6.5; 6.3 units on a scale — p=0.9704
N/A N=15 Acupressure in Pruritus for Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters
Phase 2 N=126 Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone
Chronic Pruritus
Primary: Numeric Rating Scale for Itch — 6.42; 7.8 score on a scale (0~10)
Phase 2 N=17 Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects
Pruritus
Primary: Peak Itch Intensity Between the Vehicle and Active Treatments During Non-histaminergic Itch Induction — 4.5; 3.94; 5.32; 5.79 Intensity score
N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
Phase 2 N=484 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Pruritus · Atopic Dermatitis
Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
Phase 2 N=111 The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
Chronic Kidney Disease-associated Pruritus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -3.70; -3.87 score on a scale
Phase 2 N=14 Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Epidermolysis Bullosa · Pruritus
Primary: Comparative Weekly Change in NRS Itch Score Over the 8-week Active Treatment Period — -2; -1 score/week comparative change
Phase 2 N=310 Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
Eczema · Allergy Symptoms · Psoriasis
Primary: Number of Participants With Incorrect Duration of Use of the Medication — 97; 89 Participants
Phase 2 N=49 The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application) — 6.72; -3.37 scores on a scale
Phase 3 N=295 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10 — 18.95; 25.90; 81.05; 74.10 Percentage of participants — p=0.158
Phase 3 N=285 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10 — 26.45; 20.31 Percentage of subjects — p=0.229
Phase 3 N=51 A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
Phase 2 N=20 Topical Aprepitant in Prurigo Patients
Pruritus
Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58
Phase 2 N=59 A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Primary: Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4. — -44.37; -50.37 percentage of change from…
Phase 2 N=233 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Pruritus
Primary: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10 — 46; 44 Participants — p=0.5861
Phase 2 N=69 Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Treatment-resistant Pruritus Associated With Atopic Dermatitis
Primary: Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity. — -40.5; -36.5 mm
Phase 2 N=547 B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
Atopic Dermatitis · Pruritus
Primary: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) — -2.8; -2.8; -2.1 score on a scale — p=0.0148
Phase 3 N=353 PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Prurigo Nodularis
Primary: Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14 — 24.24; 14.50 percentage of participants…
Phase 4 N=40 Management of Pruritus With Xyzal in Atopic Dermatitis
Atopic Dermatitis · Pruritus
Primary: Pruritus VAS Scores at Baseline, Week 2 and Week 4 — 7.8; 7.5; 6.10; 5.9 units on a scale
Phase 3 N=151 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Neurodermatitis
Primary: Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to…
Phase 2 N=204 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
Pruritus · Psoriasis
Primary: WI-NRS 4-point Responder Rate at Week 8 — 33.29; 21.07 % of subjects (incl. imputed data)
Phase 3 N=160 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Neurodermatitis
Primary: Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week…
Phase 2 N=24 A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Number of Patients Who Achieve at Least a 3-point Reduction in AI-NRS. — 1; 3 Participants — p=0.59
Phase 2 N=144 A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
Dermatitis, Atopic · Pruritus
Primary: Daily Peak Pruritus Numerical Rating Scale (NRS) — -45.6; -55.8; -48.3; -49.9 percent change — p=0.5483
Phase 3 N=62 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Prurigo Nodularis · Nodularis Prurigo · Prurigo
Primary: Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale — 27.3; 44.4; 36.4 percentage of subjects
Phase 3 N=130 Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
Psoriasis
Primary: Pruritus Intensity Visual Analogue Scale Score at Week 32 — 8.8; 27.1 Units on a scale — p=0.0055
Phase 2 N=122 Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
Atopic Dermatitis
Primary: Change in Pruritis Visual Analog Scale (VAS) — -12.4; -15.5; -13.9; -6.2 mm